Skip to main content
SpringerLink
Log in

Maxing out the benefits of HPV vaccine in the Netherlands

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. The study was funded by GlaxoSmithKline Biologicals SA.

  2. < 1× Belgian GDP per capita per QALY gained

References

  1. Luttjeboer J, et al. Cost-effectiveness of the prophylactic HPV vaccine: An application to the Netherlands taking non-cervical cancers and cross-protection into account. Vaccine : 24 Jun 2013. Available from: URL: http://dx.doi.org/10.1016/j.vaccine.2013.06.044.

    PubMed  Google Scholar 

  2. Demarteau N, et al. Incremental cost-effectiveness evaluation of vaccinating girls against cervical cancer pre- and post-sexual debut in Belgium. Vaccine : 15 Jun 2013. Available from: URL: http://dx.doi.org/10.1016/j.vaccine.2013.06.008.

    PubMed  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Maxing out the benefits of HPV vaccine in the Netherlands. PharmacoEcon Outcomes News 682, 8 (2013). https://doi.org/10.1007/s40274-013-0546-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-013-0546-8

Search

Navigation